medigraphic.com

2014, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2014; 52 (3)

Effect of metformin addition to an acute lymphoblastic leukemia chemotherapy treatment

Ramos-Peñafiel CO, Martínez-Murillo C, Santoyo-Sánchez A, Jiménez-Ponce F, Rozen-Fuller E, Collazo-Jaloma J, Olarte-Carrillo I, Martínez-Tovar A

Language: Spanish
References: 30
Page: 270-275
PDF size: 74.42 Kb.


ABSTRACT

Background: Recently it has been reported a benefit effect with the use of metformin in patients with malignant disease. Our objective was to evaluate the effect of adding metformin to chemotherapy regimen over the percentage of early relapse in acute lymphoblastic leukemia.
Methods: A prospective, longitudinal and experimental study was performed in patients with de novo acute lymphoblastic leukemia enrolled in the Hospital General de México. They were divided in two groups: first group received chemotherapy + metformin (850 mg three times a day); second group only received standard chemotherapy. The sample was randomized 3:1 in favor of the second group.
Results: 93 patients were included (73 treated with chemotherapy + metformin and 20 received standard chemotherapy), with 303 ± 53 days of follow-up. Complete remission was higher in the group without metformin (81.3 % [n = 61] versus 70 % [n = 14]), which also presented more patients with relapse (47.9 % versus 25 %). Overall survival at one year was of 68 % and free survival disease was 64 %, without significant differences between groups. Absence of metformin was the only variable of adverse prognostic considered significant (p = 0.55). Cox regression showed that adding metfomin reduced 56 % the risk of relapse.
Conclusions: The adding metformin to the treatment of leukemias showed that was useful in our research. However, randomized and double- blind studies must be designed in order to express final recommendations about its use.


REFERENCES

  1. Faderl S, O’Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, et al. Adult acute lymphoblastic leukemia. Concepts and strategies. Cancer. 2010;116(5):1165-76.

  2. Curado MP, Pontes T, Guerra-YI ME, Cancela MC. Leukemia mortality among children, adolescents, and young adults in Latin America. Rev Panam Salud Publica. 2011;29(2):96-102.

  3. Tirado-Gómez L, Mohar-Betancourt A. Epidemiología de las neoplasias hemato-oncológicas. Cancerologia. 2007;2:109-20.

  4. Jeha S. New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):76-88.

  5. Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology. 2011;25 (4):328-35.

  6. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukemia. Lancet. 2013;381(9881):1943-35.

  7. Harned TM, Gaynon P. Relapsed acute lymphoblastic leukemia: Current status and future opportunities. Curr Oncol Res. 2008;10(6):453-8.

  8. Liao KF, Lai SW, Li CI. The impact of anti-diabetic drugs on colorrectal cancer risk in a large cohorte of women with diabetes. Libyan J Med. 2012;7: 10.3402/ljm.v7i0.17532. Disponible en http://www. libyanjournalofmedicine.net/index.php/ljm/article/ view/17532

  9. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose- lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia. 2010;53(8):1631-7.

  10. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes. A meta-analysis. Oncologist. 2012;17(6):813-22.

  11. La Vecchia C, Bosetti C. Metformin: Are potencial benefi ts on cancer risk extended to cancer survival. Oncologist. 2013;18(12):1245-7.

  12. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol. 2011;126(3-5):113-20.

  13. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: Taking away the candy for cancer? Eur J Cancer. 2010;46 (13):2369-80.

  14. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: Translational challenger. J Mol Endocrinol. 2012;48(3):R31-43.

  15. Han D, Li SJ, Zhu YT, Liu L, Li MX. LKB1/AMPK/ mTOR signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev. 2013;14(7):4033-9.

  16. Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, et al. Metformin, a diabetes drug, eliminates tumor- initiating hepatocellular carcinoma cells. PLoS One. 2013. doi: 10.1371/journal.pone.0070010

  17. Sen S, Kundu BK, Wu HC, Hashmi SS, Guthrie P, Locke LW. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc. 2013;17;2(3):e004796.

  18. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485(7400): 661-5.

  19. Russo GL, Russo M, Ungaro P. AMP-activated protein kinase: A target for old drugs against diabetes and cancer. Biochem Pharmacol. 2013;86(3):339-50.

  20. Petrushev B, Tomuleasa C, Soritau O, Aldea M, Pop T, Susman S, et al. Metformin plus piaf combination chemotherapy for hepatocellular carcinoma. Exp Oncol. 2012;34(1):17-24.

  21. Soritau O, Tomuleasa C, Aldea M, Petrushev B, Susman S, Gheban D, et al. Metformin plus temozolomide- based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON. 2011;16(2):282-9.

  22. Haijar J, Habra MA, Naing A. Metformin: An old drug with new potential. Expert Opin Invest Drugs. 2013; 22(12):1511-7.

  23. Leclerc GM, Leclerc GJ, Kuznetsov JN, De Salvo J, Barredo JC. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblast. PLlos One. 2013;8(8):e74420.

  24. Penney KL, Stampfer MJ. The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol. 2013;31(25):3054-5.

  25. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol. 2014;32(1):49.e7-14.

  26. Hwang AL, Haynes K, Hwang WT, Yang YX. Metformin and survival in pancreatic cancer: A retrospective cohort study. Pancreas. 2013;42(7):1054-9.

  27. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care. 2013;36(10): 3018-26.

  28. Wang SS, Hsiao R, Limpar MM, Lomahan S, Tran TA, Maloney NJ, et al. Destabilization of MYC/ MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin. Int J Mol Med. 2014;33(1):35-42.

  29. Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget. 2011;2(12):1322-8.

  30. Rosilio C, Lounnas N, Nebout M, Imbert V, Hagenbeek T, Spits H, et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-defi - cient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett. 2013;336(1):114-6.




2020     |     www.medigraphic.com